Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
- Additional Dosage of Edoxaban Filed in Japan for Elderly with High Bleeding Risk
September 14, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
- 1st Japanese COVID-19 Patient Enrolled in Global PIII of Ultomiris: Alexion
September 11, 2020
- Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
September 11, 2020
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
- Hisamitsu Seeks Label Expansion for Fentos Tape to Pediatric Cancer Pain
September 11, 2020
- MSD Files Keytruda for MSI-H Colorectal Cancer
September 11, 2020
- RegeNephron, Kirin Join Hands on Cell Therapy Process Development
September 10, 2020
- Takeda to Divest Non-Core Products Sold in Europe, Canada to Cheplapharm
September 10, 2020
- Japan Ethical Drug Sales Down 4.9% in July: Crecon
September 9, 2020
- SymBio Setting Up Standalone Sales System for Treakisym in Japan
September 9, 2020
- Eisai Succeeds Parkinson’s Disease Med Equfina from Meiji Pharma on Sept. 23
September 8, 2020
- Keytruda Returns to Top Spot After 2 Months in August Sales Ranking: Encise
September 7, 2020
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
September 7, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura
September 4, 2020
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…